Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions

by Osama S. Mohammad, Michael D. Nyquist, Michael T. Schweizer, Stephen P. Balk, Eva Corey, Stephen Plymate, Peter S. Nelson, Elahe A. Mostaghel
Published 2017-12-01

Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues.

by Michelle L Christian, Zachary L Demorest, Colby G Starker, Mark J Osborn, Michael D Nyquist, Yong Zhang, Daniel F Carlson, Philip Bradley, Adam J Bogdanove, Daniel F Voytas
Published 2012-01-01

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

by Michael D. Nyquist, Alexandra Corella, Ilsa Coleman, Navonil De Sarkar, Arja Kaipainen, Gavin Ha, Roman Gulati, Lisa Ang, Payel Chatterjee, Jared Lucas, Colin Pritchard, Gail Risbridger, John Isaacs, Bruce Montgomery, Colm Morrissey, Eva Corey, Peter S. Nelson
Published 2020-05-01